Abstract : We propose a hybrid quantum–classical framework that integrates variational quantum machine learning (QML) for molecular binding affinity prediction with quantum annealing for Pareto-optimal drug formulation design. Leveraging a four-qubit variational circuit, our QML model achieves superior predictive performance compared to state-of-the-art classical baselines, effectively capturing complex molecular interactions. In parallel, we formulate drug formulation optimization as a Quadratic Unconstrained Binary Optimization (QUBO) problem and solve it using D-Wave’s quantum annealer, enabling efficient identification of Pareto-optimal solutions that balance bioavailability, toxicity, and stability. By unifying predictive modeling and combinatorial optimization within a single pipeline, our framework demonstrates the potential of near-term quantum devices to accelerate and enhance critical stages of drug discovery. These findings underscore the transformative role of NISQ-era algorithms in bridging molecular informatics and formulation design, paving the way for scalable, data-driven pharmaceutical innovation.
Abstract : We propose a hybrid quantum–classical framework that integrates variational quantum machine learning (QML) for molecular binding affinity prediction with quantum annealing for Pareto-optimal drug formulation design. Leveraging a four-qubit variational circuit, our QML model achieves superior predictive performance compared to state-of-the-art classical baselines, effectively capturing complex molecular interactions. In parallel, we formulate drug formulation optimization as a Quadratic Unconstrained Binary Optimization (QUBO) problem and solve it using D-Wave’s quantum annealer, enabling efficient identification of Pareto-optimal solutions that balance bioavailability, toxicity, and stability. By unifying predictive modeling and combinatorial optimization within a single pipeline, our framework demonstrates the potential of near-term quantum devices to accelerate and enhance critical stages of drug discovery. These findings underscore the transformative role of NISQ-era algorithms in bridging molecular informatics and formulation design, paving the way for scalable, data-driven pharmaceutical innovation.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
Quantum Machine Learning (QML) offers a transformative approach to drug design and optimization, addressing longstanding challenges in identifying novel drug candidates and refining existing ones. This paper explores the potential of QML to accelerate the drug discovery process by leveraging quantum algorithms for molecular structure exploration and optimization. We present a novel framework incorporating quantum simulation and machine learning, demonstrating its efficacy in predicting drug-target interactions and optimizing molecular properties. The core mechanism centers around accelerating the identification of promising compounds through enhanced molecular search and optimization, while quantum computational modeling provides unprecedented precision. The integration of quantum machine learning with traditional drug design methods promises to significantly reduce development time and costs, ultimately impacting the pharmaceutical industry.
Quantum machine learning (QML) has attracted significant interest in drug discovery due to its potential to model complex molecular interactions and improve prediction accuracy for protein-ligand binding affinity. However, most existing hybrid quantum-classical approaches rely on static architectures that apply quantum computation uniformly across all samples, regardless of molecular complexity or prediction confidence. Such static execution strategies lead to inefficient quantum resource utilization and limit scalability on near-term noisy intermediatescale quantum (NISQ) devices. In this paper, we propose an uncertainty-aware adaptive hybrid quantum-classical learning framework for protein-ligand binding affinity prediction that treats quantum computation as a selectively invoked resource rather than a constant component of the learning pipeline. The proposed framework first employs a classical ensemble-based regression model to generate binding affinity predictions along with an associated uncertainty estimate derived from ensemble variance. This uncertainty information is then used by a decision mechanism to dynamically select between classical-only inference, shallow quantum circuit execution, or deep quantum circuit execution. By adapting the quantum circuit depth and invocation frequency to the predicted uncertainty, the framework enables decision-centric allocation of quantum resources. Experimental evaluation of binding affinity data demonstrates that the recommended adaptive framework utilizes around 76 % less quantum resources than static hybrid quantum learning methods that use fixed-depth quantum circuits for all samples. The framework also preserves decision-level functionality and a steady inference workflow. These findings highlight the effectiveness of uncertainty-guided adaptivity as a practical strategy and offer a scalable foundation for future quantum-enhanced molecular learning.method for incorporating QML into drug development pipelines while taking hardware constraints into consideration.
This paper explores the potential of quantum machine learning (QML) in revolutionizing drug molecule design. Traditional drug discovery is a time-consuming and expensive process, often hampered by the limitations of classical computational methods in accurately simulating molecular interactions. Quantum computing, with its inherent ability to model quantum phenomena, offers a promising avenue for overcoming these challenges. This work investigates the application of QML algorithms to predict molecular properties, simulate drug-target interactions, and ultimately guide the design of novel drug molecules. Specifically, we outline a framework leveraging quantum algorithms for variational quantum eigensolver (VQE) and quantum approximate optimization algorithm (QAOA) to tackle the complexities of molecular simulations. The core claim is that QML can accelerate the drug development pipeline by providing more accurate and efficient predictions. The mechanism relies on the ability of QML models to capture the subtle quantum effects governing molecular interactions, leading to improved predictions of binding affinities, ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties, and overall drug efficacy. This paper lays the groundwork for future research in this emerging field, highlighting the potential for QML to significantly reshape the landscape of pharmaceutical research and development.
Artificial intelligence (AI) has greatly expanded the generative capacity of drug discovery, yet the ability to translate large candidate pools into structured, resource-aware decisions remains limited. This review addresses this emerging optimization bottleneck by examining quantum annealing as a potential decision-optimization layer within hybrid computational workflows. We focus on discrete, constraint-dominated tasks-such as compound subset selection, combinatorial design, and multi-objective prioritization-that can be formulated as quadratic unconstrained binary optimization (QUBO) problems. Rather than positioning quantum annealing as a predictive tool, we analyze its role as a complementary optimization interface integrated with AI-generated scores. We further discuss practical implementation considerations, including embedding overhead, noise, scalability, and benchmarking challenges. By emphasizing workflow-level design and rigorous evaluation, this review provides a pragmatic framework for assessing annealing-based optimization in drug discovery and related data-intensive scientific domains.
Abstract: This study explores the implementation of hybrid quantum-classical algorithms in the realm of drug discovery and molecular simulation, with an emphasis on optimizing molecular interaction prediction. The integration of quantum computing paradigms, particularly the Variational Quantum Eigensolver (VQE), with classical machine learning techniques is evaluated for its efficacy in simulating molecular systems. Key results demonstrate superior accuracy in predicting binding affinities and reaction energetics using the hybrid models compared to traditional methods. The findings offer significant implications for accelerating the drug development pipeline, particularly in early-stage candidate screening. Keywords: Hybrid computing, Quantum simulation, Molecular interaction, Drug discovery, Variational Quantum Eigensolver, Quantum-classical integration